Back to top
more

ProQR Therapeutics (PRQR)

(Real Time Quote from BATS)

$2.01 USD

2.01
21,656

-0.05 (-2.43%)

Updated Aug 7, 2025 09:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Techne (TECH) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 9.80% and 0.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?

by Zacks Equity Research

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of -42.86% and 51.53%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Krystal Biotech, Inc. (KRYS) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Krystal Biotech (KRYS) delivered earnings and revenue surprises of 8.33% and 0.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Best Momentum Stocks to Buy for October 2nd

by Zacks Equity Research

BRFS, SNAX, and PCQR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 2, 2024.

Zacks Equity Research

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 15.79% and 9.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GSK (GSK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cara (CARA) delivered earnings and revenue surprises of -3.51% and 28.60%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is ProQR (PRQR) Stock a Solid Choice Right Now?

by Zacks Equity Research

ProQR (PRQR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 2.13% and 22.98%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -11.11% and 7.23%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 26.32% and 54.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of 0% and 75.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -23.08% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will ProQR (PRQR) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More

by Zacks Equity Research

Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.

Zacks Equity Research

ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly

by Zacks Equity Research

ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new genetic medicines.

Zacks Equity Research

ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of -47.83% and 7.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProQR (PRQR) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of 15.38% and 9.38%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ProQR (PRQR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of 12% and 16.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?